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INTRODUCTION 
 
Enterobacteriaceae are Gram-negative bacilli at are commensals in the intestine. They can 
however cause infections ranging from urinary tract infection (cystitis, pyelonephritis), 
septicaemia, pneumonia, meningitis and device related infections. They are a common source 
of community acquired and nosocomial infections, with Escherichia coli being the most 
common pathogen. 
Spread of infections can be by contaminated human hands, contaminated food and water. The 
bacteria acquire genetic material via horizontal gene transfer which is plasmid or transposon 
mediated and acquire multidrug resistance. (1) 
Since the early 2000’s Extended Spectrum Beta-Lactamases (ESBLs) have been reported 
worldwide.  A study done in south India in 2007, where 131 episodes of bacteremia were 
studied as a prospective cohort revealed that 77.86% episodes were caused by E.coli, 62% of 
which were nosocomial acquired. Out of these isolates, 73.5% of the E.coli and 72.4% 
Klebsiella were ESBL. ESBL conf---ers resistance to all beta-lactams except Carbapenems.  
Carbapenems were found to be most active among all antimicrobials tested, and conclusions 
were made that in patients with serious life threatening infection with ESBL empiric antibiotic 
of choice should be Carbapenem. (2) This finding has been corroborated by many studies in 
India and worldwide. This has led to the widespread use of Carbapenem. 
Carbapenems (imipenem, meropenem, ertapenem, doripenem) are latest molecules with broad 
spectrum activity in beta lactams. Drawback of wide spread use of Carbapenem is the 
emergence of Carbapenem resistance. 
Emergence of novel beta-lactamases with direct Carbapenem hydrolyzing activity has 
contributed to Carbapenem resistance .(3) 
Carbapenem acquire resistance by: 
1) Acquisition of carbapenemase genes that encode for enzymes capable of degrading 
Carbapenem. 
2) A decrease in uptake of antibiotics by qualitative and/or quantitative deficiency of porin 
expression in association with over expression of Beta lactamases that poses very weak affinity 
for Carbapenem (1) 
Since Carbapenem are now the first line of therapy in severe infections caused by multi drug 
resistant gram negative bacilli, the emergence of resistance to Carbapenem is proving to be a 
threat the heath and health care worldwide. 
As per previous studies, exposure to health care and antimicrobials are the most important risk 
factors to developing CRE bacteremia. (3) 
Patel et al found that invasive infections with Klebsiella pneumoniae was independently 
associated with recent organ/stem cell transplantation, mechanical ventilation and longer in 
hospital stay.(4) ICU stay and poor functional status have also been attributed as risk factors 
that cause increased mortality.(5) 
Few therapeutic options remain available for the treatment of Carbapenem resistant 
Enterobactericeae, and are most often limited to colistin and tigecycline. (6) However , the 
treatment is often restricted by their side-effects as well as uncertain in vivo activity.(7)  
The prevalence continues to grow globally while being subject to large regional variation. (7) 
A case control study, the impact of finding Klebsiella pneumoniae isolates in bloodstream was 
estimated in patients with Carbapenem resistant Klebsiella pneumoniae infections. It was 
estimated that the mortality was 72% for blood stream infections compared to 22% in patients 
with infections at other sites.(8)  
In a series of 60 cases of CR-KP BSI, 14 days and all cause in hospital mortality  was 42% and 
58% respectively.(7) 
Optimal therapy for CRE BSI is still under dispute and development of newer antibiotic 
molecules are underway. Retrospective comparisons favour combination therapy over single 
agent therapy with absolute differences in mortality ranging from 20.2% to 46.7%.(9) (10) 
A study done in a tertiary hospital in Mumbai revealed that colistin monotherapy may 
be non-inferior compared to combination therapy for treating CRE BSI , however 
combined use of colistin with Carbapenem can provide good therapeutic option and 
needs further investigation.(11) 
Therefore, investigation of risk factors for development of CRE bacteremia and 
appropriate antibiotic therapy is warranted.  
 
 
 
 
PROPOSED STUDY 
In this prospective cohort study, we plan to assess the clinical profile and outcome of patients,  
with Carbapenem Resistant Enterobactericeae (Klebsiella spp and Escherichia coli) blood 
stream infection requiring admission into a medical, surgical ward or ICU in a tertiary care 
centre in South India. 
 
 
 
 
 
 
 
 
 
 
 
 
AIM 
To assess treatment outcomes in patients with Carbapenem resistant Enterobactericeae (CRE) 
bloodstream infections (BSI) being treated in the medical ward, surgical ward and ICU in 
tertiary care hospital in South India 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVES 
 
1) To determine the rate of 14-day all-cause mortality in patients with CRE BSI who are 
admitted to general wards or medical and surgical ICU and HDU. 
2) To assess factors associated with mortality in patients with CRE BSI. 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
SETTING 
The Christian Medical College is a 2400 bed teaching hospital in Vellore, South 
India. Though it caters to approximately 1 million citizens of the town it also serves 
patients from all over India and South-East India. 
This study has been conducted among patients with CRE bacteremia in all Medical 
wards, Medical ICU and HDU, surgical ICU and HDU, certain approved Surgical 
and specialty wards. 
Duration: May 2017 till July 2018 as a prospective study. 
STUDY DESIGN 
Prospective observational study 
 
 
 
 
 
 
 
 INCLUSION CRITERIA 
1. Patient age more than or equal to 18 years, who have given written informed consent 
2. Patients who are currently admitted in CMC Hospital, Vellore 
3. Patient with monomicrobial CRE BSI 
4. Current CRE bacteremia being the first episode of BSI, patients with second episode of 
CRE during the same admission were registered only once.  
 
EXCLUSION CRITERIA 
1. Patients below the age of 18 
2. Patients who are not currently admitted in the hospital 
3. Patients who do not give consent 
4. Patients with previous bacteremic illness during the current admission 
 
 
 
 
 
 
METHODS 
Patients with confirmed CRE BSI (Klebsiella spp. or Escherichia coli) were identified 
through a registry in the Department of Microbiology. Blood cultures were 
predominantly drawn from peripheral venipuncture after observing aseptic precautions. 
In patients with CLABSI, a paired peripheral venipuncture sample was also obtained. 
Sequential patients with CRE BSI were then enrolled in the study if they met the 
inclusion criteria as specified above. In all patients only the first episode of bacteremia 
was included for analysis. 
A study questionnaire with relevant information was formulated. This included 
demographic details, severity of illness (APACHE II score and Pitt’s bacteremia score), 
INCREMENT CPE score (12) co- morbidities such as underlying Diabetes Mellitus and 
systemic hypertension, the Charlson Comorbidity Index was also assessed, immune 
status (Sero-positive status, underlying Hepatitis B or Hepatitis C infection) and 
primary source of bacteremia. 
Pitt’s Bacteremia Score is a score that takes into account vital signs, mechanical 
ventilation and mental status, a score of more than 4 is suggestive of severe infection. 
The Acute Physiology and Chronic Health Evaluation (APACHE II), is a tool used to 
estimate acute severity of illness and mortality. The APACHE II score is made of both 
physiological variables and disease-related variables. The APACHE II score can have 
a value from the range of 0 to 71 points. 
During the study period, the administration of antibiotics and other therapy related 
decisions, were made solely by the treating physician and were not influenced by this 
study. 
Demographic details, and parameters for assessment were documented from the 
patient’s hospital chart, after written informed consent was obtained from the patient or 
their relatives. Details used in assessment of severity of illness, including temperature, 
presence of hypotension and laboratory parameters were obtained of the day that the 
blood culture that grew the isolate of interest had been taken.  
Primary source of the infection was defined as pneumonia, urinary tract infection, 
surgical wounds and primary bloodstream infections, with catheter related blood stream 
infections included with primary blood stream infections in accordance with the 
definitions that have been established by the Centers for Disease Control and 
Prevention.(13) 
 
 
 
 
 
 
 
MICROBIOLOGICAL METHODS 
For all patients enrolled in the study, 5-8 ml of blood was collected, using standard 
precautions, in adult blood culture bottles (BacTAlert). This was then processed by 
semi-automated blood culture system (BacT/Alert; BioMérieux, Marcyľ Etoile, 
France). Standard microbiological methods were used to identify the causative 
organism. Disk diffusion method was used to for antibiotic susceptibility testing (AST). 
The interpretation was based on Clinical Laboratory Standards Institute (CLSI) 
recommendations.  
 
Disk diffusion by Kirby-Bauer method 
 
CLSI recommends this method for routine testing. Accuracy and reproducibility is 
insured by maintaining a standard set of procedures.  
Requirements: 
1. Sterile broth medium in 1.5 ml quantities (nutrient broth / Mueller Hinton broth)  
2. MHBA for S. pneumoniae and other Streptococci 
3. MHA for Non-fastidious organisms. 
4. HTM for Haemophilus spp. 
5. GC agar with 1% growth supplements for Neisseria spp. 
6. Calibrated loop of  2 mm diameter 
7. Antibiotic solution 
8. Sterile filter paper disks / Commercial disks 
9. Pasteur pipettes sterile 
10. Cotton swabs sterile 
11. Normal saline and  / Nutrient broth 
12. McFarland BaSO4 turbidity standard 0.5 
13. Sterile forceps / needle / disk dispenser 
14. 12 x 100 mm sterile test tubes  
15. Measuring scales / sliding calipers  
16. Table lamp 
17. Zone diameter interpretation charts 
18. Quality control reference strains  
19. Discard jar with disinfectant 
 
Antimicrobials: 
Antimicrobials for testing may be prepared in house (from pure substance) or are also 
available as commercial disk of standard size and strength. 
Commercial disk:  
1. Each particular agent recommends the proper temperature for storage of the disk 
cartridges. Certain specific agents like imipenem, cefaclor, and clavulanic acid 
combinations should be frozen till day of testing, in view of their labile nature. 
2. For cartridges that are stored in a freezer, they should be removed from storage 
one or two hours prior to testing to bring it at room temperature. This is done in 
order to prevent condensation forming on the disks. 
3. Discard all disks that are past the expiry date. 
 Preparation of antimicrobial solution in-house: 
Preparation of stock solution: 
1. Pure substance of antimicrobial agents may be received in powder or tablet form. 
Preparations intended for parenteral injections should not be used.  
2. Using sterile glassware, required concentrations of the stock solution are 
obtained by accurately weighing the powders and dissolving them in appropriate 
diluents.  
3. Antibiotic stock solution should be evaluated against standard strains of stock 
cultures. The stock can be aliquoted in 5 ml volumes and frozen at -20ºC or -
60ºC, if satisfactory. 
4. Antibiotic solution can be prepared with the following formula: 
 
Weight (mg) = Volume (mL) • Concentration (μg/mL) 
Potency (μg/mg) 
Or 
Volume (mL) = Weight (mg) • Potency (μg/mg) 
Concentration (μg/mL)  
 
 
 
 
 
 Preparation of inoculum: 
Either growth method or direct suspension method can be used to prepare the inoculum. 
 
For non-fastidious organisms the growth method is preferred. This is also preferred 
when smooth suspension of the organism cannot be made. 
1. Touch 8 or 10 well isolated colonies that are of the same morphological type 
with a sterile needle / loop. 
2. Inoculate into 1.5 ml of a sterile suitable broth.  
3. To produce a bacterial suspension of moderate turbidity, the inoculum should be 
incubated at 35 – 37oC for   2 – 6 hours.  
4. Adjust the turbidity of the broth to McFarland barium sulphate standard 0.5 with 
sterile saline / broth. This results in a suspension containing approximately 1 to 
2 x 108 CFU/ml for E.coli ATCC 25922.   
Inoculation of test plates 
1. According to the number of antibiotics used, mark the plates into five sections 
(100 mm petri-dish). 
2. The plates need to be inoculated within 15 minutes of preparation of suspension 
in order to avoid change in the density. 
3. Removes excess fluid by dipping a sterile cotton swab into the suspension. 
4. By streaking the swab over the sterile agar surface, inoculate the dried surface of 
a Mueller-Hinton agar plate. 
5. The lid may be left ajar for 3 to 5 minutes, to allow for excess surface moisture 
to be absorbed before applying the drug impregnated disks. 
 
Application of antimicrobial disk 
1. Within 15 minutes of inoculation of the culture, the antimicrobial disks should 
be dispensed on the agar plate.  
2. Complete contact with the agar surface needs to be ensured by pressing each disk 
down individually.  
3. A disk should not be relocated once it has come into contact with the agar 
surface.   
4. For antimicrobial solution that is prepared in house, a 2 mm calibrated loop is 
used to deliver 5µl of the solution into 6 mm disk that is prepared from 
Whatmann No.2 filter paper, and placed on the surface of the plate. 
5. After the disks are applied, incubate the plates in an inverted position in an 
incubator set to 35±2ºC within 15 minutes. 
Reading and interpretation of results: 
1. Only when the zone size for the QC organism is within the expected zone size 
range should reading for the test isolate be taken. 
2. Each plate is examined after 16 – 18 hours of incubation.  
3. Resulting zones of inhibition will be clear and there will be a confluent lawn of 
growth if the inoculum was correct and the plate was accurately streaked.  
4. Zone edge: is the point of abrupt diminution of growth. 
5. Measure the diameters of the zones of complete inhibition, including the 
diameter of the disk.  
6. Zones are measured to the nearest whole millimeter. 
The area where no obvious, visible growth can be detected is the zone margin.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEFINITIONS 
1. An episode of bacteremia is defined as the period of 14 days from the time of 
collection of the first blood culture positive for E. coli or Klebsiella spp.  
2. Nosocomial bacteremia: defined as E. coli or Klebsiella spp. bacteremia occurring 
among patients more than 48 hours after admission to the hospital or among those 
patients who had an invasive procedure done (minor surgical procedure, intravenous 
administration of drugs or placement of a urinary catheter) as an outpatient and the 
bacteremia was attributable to that procedure.  
3. Previous antibiotic therapy is defined as antibiotics given for at least 2 days within 
the 14 days before an episode of E. coli or Klebsiella spp. bacteremia. 
4. Mortality was death from any cause within 14 days from the date of the first positive 
blood culture for E. coli or Klebsiella spp.  
5. Empiric antibiotic treatment was the antibiotic(s) administered from the time of 
obtaining blood culture, and continued till availability of AST report 
6. Targeted antibiotic treatment was defined as antibiotics started once the AST 
report was available. 
7. Appropriate antibiotic treatment (empirical and targeted) was defined as receipt 
of at least one antimicrobial to which the bacterial isolate was susceptible in-vitro. 
8. Inappropriate therapy was defined as administration of antimicrobials that did not 
have in-vitro activity against the isolate of interest. 
 
 
SAMPLE SIZE CALCULATIONS 
Based on a previous study the mortality of patients with CRE is described to be 42.6%.  
Based on this information, the sample size was calculated for: 
Objective (1) using the formula, n=4p (1-p)/d2 = (4*.43*.57)/ (.07*.07) =164. Here p 
is the expected proportion of mortality and d is the absolute precision.  
Objective (2), to find the significant predictors of mortality, the required number is 
approximately 224.  
Hence the sample size of this study is decided to be 250. 
INSTITUTIONAL REVIEW BOARD 
The institutional review board and ethics committee approved this study. The research 
funding was obtained from the fluid research grant of the institution. 
IRB Minute Number: 10566 (OBSERVE) (8/3/2017) 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
Bloodstream infections are a major cause of morbidity and mortality. Bacteremia due 
to Gram-negative bacilli is a significant problem encountered as both community 
acquired and hospital acquired infections. These organisms present problems with 
regards to antibiotic therapy because of the increasing drug resistance (14). Gram-
negative bacteremia with septic shock has been estimated to have a mortality rate of 12 
to 38 percent; depending, on whether the patient receives timely and appropriate 
antibiotic therapy (15).  
EPIDEMIOLOGY 
Gram-negative bacilli cause approximately a quarter to a half of all bloodstream 
infections, whether the infection is hospital or community acquired, depending on 
geographic region, and other patient risk factors. 
Community-acquired infections 
Gram-negative bacilli cause a high proportion of community-acquired BSI, as they are 
more likely related to primary infections of the urinary tract, abdomen, and respiratory 
tract. 
In a study conducted in two tertiary care centers in the United States, community-
acquired bloodstream infections were due to Gram-negative bacilli in 45% cases, 
whereas they caused 31 percent of hospital-acquired infections (16). A systematic 
review of studies from South and Southeast Asia , wherein  among community-acquired 
BSI, Gram-negative organisms were the causative in 60 percent of patients (17). 
Gram-negative BSI as a community-acquired infection is commonly seen in the elderly 
population. This was evidenced in a retrospective review of 238 patients, 65 years of 
age and above, wherein a Gram-negative organism was the etiologic agent in 36 percent 
of cases (18). 
Hospital-acquired infections 
In the United States of America, the National Nosocomial Infections Surveillance 
(NNIS) System reported that from 1986 to 2003 the proportion of gram negative BSI in 
ICU patients remained static at approximately 25 to 30 percent (19).  
However, several single centre studies have shown an increase in the proportion of 
Gram-negative infections among patients with catheter-related BSI. A single large 
United States tertiary care hospital reported a significant increase in the proportion of 
gram-negative BSI from 15.9 percent in 1999 to 24.1 percent in 2003 (20). Several 
subsequent reports from Europe have shown a similar trend in the proportion of Gram-
negative catheter-related BSI (21,22).  Increasing proportions of Gram-negative 
catheter-related bloodstream infections, may be related to improved prevention efforts 
aimed at Gram-positive central line infections, increasing antimicrobial 
resistance, and/or changes in surveillance practices (23–25). Many of these factors are 
impacted by local infection prevention practices and the geographical prevalence of 
drug-resistance. 
Globally, the proportion of bloodstream infections caused by Gram-negative bacilli 
differs by geographic region.  
Data from the SENTRY Antimicrobial Surveillance Program from 1997 to 2002 
demonstrated that the proportion of Gram-negative bacteremia was greater in Europe 
(43 percent) and Latin America (44 percent), than that identified in North America (35 
percent) (26).  A study from the European Antimicrobial Resistance Surveillance 
System, reported that the frequency of bacteremia due to Escherichia coli increased by 
8.1 percent per year from 2002 to 2008. The additional caseload was being attributed to 
increasing antimicrobial resistance (27). 
Seasonality and the effect of warmer climates may partially explain these geographical 
differences. Several studies have demonstrated seasonal trends in gram-negative 
bacteremia in multiple continents and involving various pathogens, 
including Acinetobacter spp., E. coli, Enterobacter spp., Klebsiella pneumoniae, 
and Pseudomonas aeruginosa (28–30).  
 
 
 
 
 
 
 
 
Risk factors associated with Gram-negative bacteremia 
Most hospitalized patients with Gram-negative bacteremia have at least one comorbid 
condition (31). In a study of 326 patients with Gram-negative bacteremia, comorbid 
conditions were identified in (97 percent) (32). Conditions identified in this study 
included(32–35): 
• Haematopoietic stem cell transplant 
• Liver failure  
• Serum albumin <3 G/dL  
• Solid organ transplant 
• Diabetes mellitus 
• Pulmonary disease 
• Chronic hemodialysis 
• HIV infection  
• Treatment with glucocorticoids 
 
 
 
 
SOURCE OF INFECTION 
Determining the source of infection is critical to make appropriate therapeutic decisions. 
This includes assessment of the most likely pathogen, and subsequently initiation of 
appropriate empiric therapy depending on the site of the primary infection. Among 
critically ill patients, common sources of Gram-negative BSI include the respiratory 
tract and central venous catheters (36). Several studies of elderly patients in the 
community, have identified the urinary tract as the most frequent source of Gram-
negative BSI  (37,38). Infections of the gastrointestinal tract, biliary tract, and skin or 
soft tissues are less frequent sources of bloodstream infections. 
MICROBIOLOGY 
The frequency of specific Gram-negative bacilli responsible for BSI differs depending 
on whether the onset of the infection, is in the hospital or community and the likely 
primary source of infection. 
Hospital-acquired gram-negative bacillary BSI identified from a large database of acute 
care hospitals in the United States, distribution of pathogens was noted  as follows(39): 
E. coli – 18 percent 
K. pneumoniae – 16 percent 
P. aeruginosa – 8 percent 
Proteus spp – 1 percent 
Other Gram-negative bacteria – 56 percent 
Patients in the ICU generally are on empiric antibiotics, which increases the risk of 
infections with P. aeruginosa and other non-fermenting Gram-negative bacilli.  
Infections with E. coli predominate in cases of community-onset Gram-negative BSI. 
This was depicted in a study done in Italy wherein the following distribution was noted. 
(40)  E. coli – 76 percent 
P. aeruginosa – 7.9 percent 
K. pneumoniae – 5.4 percent 
Proteus mirabilis – 4.2 percent 
Enterobacter spp – 3.7 percent 
 
 
 
 
 
 
 
 
 
ANTIBIOTIC RESISTANCE 
The treatment of Gram-negative BSI is increasingly complicated by the rising 
prevalence of multidrug-resistant Gram-negative bacilli strains. Susceptible 
Enterobacteriaceae become resistant to antimicrobial agents by acquiring resistance 
genes from other bacteria or through mutation and selection.  
The burden of antimicrobial resistance among bloodstream infections caused by Gram-
negative organisms is profound. Between 2009 and 2010 , in the United States alone,  
among the 27,766 CLABSI reported to the National Healthcare Safety Network, the 
prevalence of resistance to broad-spectrum antibiotics to be(23): 
●K. pneumoniae – 29 and 13 percent resistant to third or fourth generation 
cephalosporins and carbapenems, respectively 
●E. coli – 42, 19, and 2 percent resistant to fluoroquinolones, third or fourth 
generation cephalosporins and carbapenems, respectively 
●Enterobacter spp – 37 percent resistant to third or fourth generation 
cephalosporins 
●P. aeruginosa – 31, 26, and 26 percent resistant to fluoroquinolones, third or 
fourth generation cephalosporins, and carbapenems, respectively 
●A. baumannii – 67 percent resistant to carbapenems 
In addition to these, there has been emergence and dissemination of extended-spectrum 
beta-lactamases and carbapenemases. 
These multidrug-resistant pathogens are no longer limited to an in hospital acquired 
infection. Patients are frequently infected or colonized with these pathogens in the 
community and in long term care facilities(41–43). 
(44)  Figure 1: resistance mechanisms in Enterobactericeae 
 
 
 
 
 
 
Extended-spectrum beta-lactamases 
Extended-spectrum beta-lactamases (ESBL) are enzymes that confer resistance to most 
beta-lactam antibiotics - penicillins, cephalosporins, and the monobactam aztreonam. 
Plasmids that carry ESBLs typically carry other resistance genes as well; thus, these 
organisms are frequently multidrug-resistant. 
The ESBL family is heterogeneous. SHV and TEM-type ESBLs arose by amino acid 
substitutions that allowed narrower spectrum enzymes to attack the new oxyimino-beta-
lactams. Others include members of the CTX-M family, represent plasmid acquisition 
of broad-spectrum beta-lactamases originally determined by chromosomal genes. 
ESBLs vary in activity against different oxyimino-beta-lactam substrates but do not 
affect the cephamycins (cefoxitin, cefotetan and cefmetazole) and the carbapenems 
(imipenem, meropenem, doripenem, and ertapenem).  
They are also susceptible to beta-lactamase inhibitors, such as clavulanate, sulbactam, 
and tazobactam, which consequently can be combined with a beta-lactam substrate to 
test for the presence of this resistance mechanism. 
ESBLs have been found exclusively in Gram-negative organisms, primarily 
in Klebsiella pneumoniae and Escherichia coli but also 
in Acinetobacter, Burkholderia, Citrobacter, Enterobacter, Morganella, Proteus,  
Pseudomonas, Salmonella, Serratia, and Shigella spp. 
Infection due to ESBL-producing E. coli has become widespread in hospitals around 
the world (45). Community-associated infection due to ESBL has also been recognized 
as an important clinical problem.  A substantial portion of community-onset infection 
due to ESBL-producing E. coli has been observed among patients with no discernible 
health care-associated risk factors (46). 
 
TYPES OF ESBL 
TEM beta-lactamases — the amino acid substitutions responsible for the ESBL 
phenotype cluster around the active site of the enzyme and change its configuration, 
allowing access to oxyimino-beta-lactam substrates. Single amino acid substitutions at 
positions 104, 164, 238, and 240 produce the ESBL phenotype, but ESBLs with the 
broadest spectrum usually have more than a single amino acid substitution. Based upon 
different combinations of changes, currently more than 220 TEM-type enzymes have 
been described. Not all behave as ESBL, and some, such as TEM-1 and TEM-2, only 
hydrolyze beta-lactams such as penicillins and narrow spectrum cephalosporins (47). 
Most are ESBLs, some are resistant to beta-lactamase inhibitors, and a few are both 
ESBLs and inhibitor-resistant.  
SHV beta-lactamases — ESBLs in this family also have amino acid changes around 
the active site, most commonly at positions 238 or 238 and 240. More than 190 SHV 
varieties are known, and they are found worldwide. SHV-2, SHV-5, SHV-7, and SHV-
12 are among the most common (48). Not all the SHVs are ESBL and some, such as 
SHV-1, only hydrolyze beta-lactams such as penicillins and narrow spectrum 
cephalosporins (47). 
CTX-M beta-lactamases — these enzymes were named for their greater activity 
against cefotaxime than other oxyimino-beta-lactam substrates 
(eg, ceftazidime, ceftriaxone, or cefepime). They represent acquisition of resistance due 
to plasmid acquisition of beta-lactamase genes normally found on the chromosome 
of Kluyvera species, a group of rarely pathogenic commensal organisms. 
More than 160 CTX-M enzymes have been described (49). They have been found in 
many different Enterobacteriaceae including Salmonella,  and are the most common 
ESBL type worldwide (50), and are increasingly prevalent in the United States (51). 
The proliferation of CTX-M enzymes is due not to being better beta-lactamases than 
TEM or SHV varieties but to the capture and dissemination of CTX-M genes by mobile 
genetic elements that mediate rapid and efficient spread between replicons and from 
cell to cell, especially to highly successful lineages such as E. coli ST131 and ST405 
and K. pneumoniae CC11 and ST147 (52). 
OXA beta-lactamases — OXA beta-lactamases are also plasmid-mediated beta-
lactamase variety that could hydrolyze oxacillin and related anti-staphylococcal 
penicillins. Amino acid substitutions in OXA enzymes can also give the ESBL 
phenotype. OXA-type ESBLs have been found mainly in Pseudomonas 
aeruginosa isolates from Turkey and France. OXA beta-lactamases with 
carbapenemase activity have also been described.  
Others — Other plasmid-mediated ESBL families, such as PER, VEB, and GES, are 
uncommon and have been found mainly in P. aeruginosa and at a limited number of 
geographic sites (53). In addition to conferring high-level resistance to antipseudomonal 
beta-lactams, these ESBLs also degrade cephalosporins, and monobactams. Other rare 
ESBLs found in Enterobacteriaceae are BES, SFO, and TLA.  
 
The majority of infections with ESBL-producing organisms in the hospital are caused 
by K. pneumoniae. However, over the past decade, ESBL-producing E. coli has 
emerged as an important cause of both hospital-onset and, in particular, community-
onset bacteremia. As a result, E. coli is now the most common cause of ESBL infection 
worldwide. In one series, these resistant organisms accounted for 7.3 percent of cases 
of community-onset bacteremia (54). 
Risk factors for infection with an ESBL-producing organism among patients with 
bacteremia include admission from a nursing home, the presence of a gastrostomy tube, 
transplant receipt, chronic renal failure, receipt of antibiotics within the preceding 30 
days, and length of hospital stay before infection. 
The only proven therapeutic option for severe infections caused by extended-spectrum 
beta-lactamase (ESBL)-producing organisms is the carbapenem family.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CARBAPENEM:(55) 
The term “carbapenem” is conferred to a 4:5 fused ring lactam of penicillins that contain 
a double bond between C-2 and C-3, along with the substitution of carbon for sulfur at 
C-1. 
Chemistry 
Studies from early carbapenems revealed that the carbon atom at the C-1 position played 
a major role in the potency and spectrum of carbapenems, and in their stability against 
–lactamases.   
Further research has taught us that a hydroxyethyl R2 side chain aids in resistance to 
hydrolysis by lactamases and a trans configuration of the C-5 C-6 lactam ring leads to 
greater stability against beta-lactamases.  aids in resistance to hydrolysis by lactamases 
(56). R configuration at C-8 also enhances potency.  
Mechanism of action 
 
Carbapenems enter Gram-negative bacteria through outer membrane proteins (OMPs), 
known as porins. After traversing the periplasmic space, carbapenems “permanently” 
acylate the PBPs.(57) 
PBPs are enzymes (i.e., transglycolases, transpeptidases, and carboxypeptidases) that 
catalyze the formation of peptidoglycan in the cell wall of bacteria. 
Carbapenems act as mechanism-based inhibitors of the peptidase domain of PBPs and 
can inhibit peptide crosslinking among other peptidase reactions. 
As carbapenems bind to many different PBPs, inhibiting their action, thereby causing 
autolysis at a more rapid rate than cell wall formation. This thereby weakens the 
peptidoglycan layer of the cell wall, causing the cell to burst due to osmotic pressure. 
 
(58) Figure 2: Schematic view of the cell wall in Gram-negative bacilli showing the 
outer membrane including a porin where the antibiotic can enter the cell, the 
periplasmic space where the b-lactamases are located, the cytoplasmic membrane and 
multidrug efflux pumps that can export antimicrobial agents out of the bacterial cell. 
 
 
 
Microbiological activity 
Carbapenems demonstrate a broader antimicrobial spectrum in vitro than the available 
penicillins, cephalosporins, and beta-lactam/beta-lactamase inhibitor combinations 
(59).  
Imipenem, panipenem, and doripenem are potent antibiotics against Gram-positive 
bacteria (59–61). Meropenem, biapenem, ertapenem, and doripenem are slightly more 
effective against Gram-negative organisms (59).  
Carbapenems can also be combined with other antimicrobials to treat serious infections. 
Combination therapy is a subject of intense interest, since the emergence of MDR 
pathogens often requires us to treat patients with more than one antibiotic (53,62,63).  
It is in this very niche area of infections that we encounter the catastrophic reality 
of Carbapenem Resistant Enterobactericeae. 
 
 
 
 
 
 
 
 
CARBAPENEM RESISTANCE 
Carbapenem resistance in Enterobacteriaceae is therapeutic challenge with every 
increasing prevalence, if left unchecked exudes terrifying implications for public health 
and society (62,63). These bacteria, including Escherichia coli, Klebsiella pneumoniae 
and other species, are commensals in the human gut and frequently are the cause of 
hospital acquired and community acquired  infections, ranging from the urinary, 
gastrointestinal and respiratory tracts as well as bloodstream infections (BSI) (19).  
Mediation of resistance to carbapenems among Enterobacteriaceae is by transferable 
beta-lactamase enzymes (66). Due to the occurrence of more than one resistance gene 
on the same mobile genetic elements (67),  carbapenemase producing strains are 
normally extensively drug resistant (i.e. susceptible to ≤2 antimicrobial classes) (68).  
CLASSIFICATION 
Carbapenemases are carbapenem-hydrolyzing beta-lactamases that confer resistance to 
a broad spectrum of beta-lactam substrates, including carbapenems. This mechanism is 
distinct from others such as impaired permeability due to porin mutations. 
The carbapenemases have been organized based on amino acid homology in the Ambler 
molecular classification system. Class A, C, and D beta-lactamases all share a serine 
residue in the active site, while Class B enzymes require the presence of zinc for activity 
(and hence are referred to as metallo-beta-lactamases). Classes A, B, and D are of 
greatest clinical importance among nosocomial pathogens. 
 
Class A beta-lactamases 
Class A beta-lactamases are characterized by their hydrolytic mechanisms that require 
an active-site serine at position 70 (69). These include penicillinases and 
cephalosporinases in the TEM, SHV, and CTX-M-type groups (which do not hydrolyze 
carbapenems), as well as additional groups that possess beta-lactamase (including 
carbapenemase) activity (47,69,70). 
Class A beta-lactamases with carbapenemase activity may be encoded on chromosomes 
or plasmids. Chromosomally-encoded enzymes include SME (Serratia 
marcescens enzyme), NMC (non-metalloenzyme carbapenemase) and IMI (imipenem-
hydrolyzing) beta-lactamases. Plasmid-encoded enzymes include KPC (Klebsiella 
pneumoniae carbapenemase) and GES (Guiana extended spectrum). GES has been 
described in Pseudomonas aeruginosa and K. pneumoniae (71–73).  
 
Klebsiella pneumoniae carbapenemase (KPC) 
 The most clinically important of the Class A carbapenemases is the K. pneumoniae 
carbapenemase (KPC) group. These enzymes reside on transmissible plasmids and 
confer resistance to most beta-lactams (71). Several variants of KPC enzymes have been 
identified. Some hydrolyze beta-lactams at varying rates, which may contribute to 
different susceptibility profiles in KPC-producing bacteria when tested in vitro(74,75). 
KPC can be transmitted from Klebsiella to other genera, including E. coli, P. 
aeruginosa, Citrobacter, Salmonella, Serratia, and Enterobacter spp (76–78). Another 
carbapenemase, BKC-1, has been detected in rare clinical isolates of K. pneumoniae in 
Brazil (79). 
Class B beta-lactamases 
Class B beta-lactamases are also known as the metallo-beta-lactamases (MBLs), 
because of their dependence upon zinc for efficient hydrolysis of beta-lactams. MBLs 
can be inhibited by EDTA (an ion chelator); they are not inhibited by beta-lactamase 
inhibitors such as tazobactam, clavulanate, sulbactam, and avibactam. Additional 
groups of acquired MBLs have been identified: IMP, VIM, GIM, SPM, and SIM.  
There are both naturally occurring and acquired MBLs. Naturally occurring MBLs are 
chromosomally encoded and have been described in Aeromonas 
hydrophilia, Chryseobacterium spp, and Stenotrophomonas maltophilia (80). Acquired 
MBLs consist of genes encoded on integrons residing on large plasmids that are 
transferable between both species and genera (69,81–83).  
New Delhi metallo-beta-lactamase (NDM-1) 
Enterobacteriaceae isolates carrying a novel MBL gene, the New Delhi metallo-beta-
lactamase (NDM-1), were first described in December 2009 in a Swedish patient 
hospitalized in India with an infection due to K. pneumoniae(84). 
The gene encoding this MBL is located in a very mobile genetic element, and the pattern 
of spread appears to be more complex and more unpredictable than that of the gene 
encoding KPC (84,85). The large number of resistance determinants in the isolates 
studied raise concern that this gene is an important emerging resistance trait (86). In 
general, bacteria containing NDM-1 have tested susceptible to colistin or tigecycline, 
though such susceptibility may be short-lived. 
In addition to K. pneumoniae, NDM-1 has also been identified in other 
Enterobacteriaceae (including E. coli and Enterobacter cloacae) (87) as well as non-
Enterobacteriaceae (including Acinetobacter)(88). 
Class D beta-lactamases 
Class D beta-lactamases are also referred to as OXA-type enzymes because of their 
preferential ability to hydrolyze oxacillin (rather than penicillin) (89). Enzymes in this 
group are variably affected by the beta-lactamase inhibitors clavulanate, sulbactam, or 
tazobactam. OXA carbapenemases have been identified in Acinetobacter 
baumannii (90–92) and Enterobacteriaceae (especially K. pneumoniae, E. coli, and E. 
cloacae) (93). 
Among the heterogeneous OXA group (which includes more than 100 enzymes), six 
subgroups have been identified with varying degrees of carbapenem-hydrolyzing 
activity: OXA-23, OXA-24/OXA40, OXA-48, OXA-58, OXA-143, and OXA-51. The 
first five groups are carried on transmissible plasmids, while the last group, OXA-51, 
and is chromosomally encoded. Enterobacteriaceae with OXA-48-type enzymes have 
variable susceptibility to these agents. Expression of a promoter insertion element 
(ISAba1) in OXA-23 and OXA-51 likely contributes to carbapenem resistance(94). 
 
 
EPIDEMIOLOGY 
Klebsiella pneumoniae carbapenemases 
The K. pneumoniae carbapenemase (KPC) is the most common carbapenemase in the 
United States. Following the first description of KPC from a clinical isolate of K. 
pneumoniae in the late 1990s in North Carolina (71,93), KPC-production has been 
identified in isolates from nearly every state, as of 2015 (95). In a surveillance study 
from sites in seven states from 2012 to 2013, the incidence of carbapenem-resistant 
Enterobacteriaceae isolates from urine or a sterile site was 2.93 cases per 100,000 
person years; approximately half of the submitted isolates possessed the KPC beta-
lactamase (96). 
KPC-possessing isolates have also been increasingly recovered from other regions of 
the world, including Europe (97,98), Asia (99,100), Australia (101), and South America 
(102). 
Class D carbapenemases 
 While A. baumannii carrying OXA-23-, OXA-24/40-, and OXA-58-type 
carbapenemases are of significance in Europe, they have also been encountered in 
medical centers in Eastern Asia, the Middle East, Australia, South America, and the 
United States (89). The first isolate of K. pneumoniae with OXA-48 was identified in 
Turkey (64). Enterobacteriaceae with OXA-48-type enzymes have also identified in the 
United States, Europe, the Middle East, and Northern Africa. 
Of greater importance to our study population is the metallo-beta-lactamases, of which 
NDM-1 was first identified in patients who had sought treatment in India. 
Metallo-beta-lactamases 
Metallo-beta-lactamases (MBLs) were initially described in Japan in 1991(103). MBLs 
have since been described in other parts of Asia, Europe, North America, South 
America, and Australia (104–106). The transfer of patients between hospitals and the 
increase in international travel may be important factors in the geographical 
dissemination of MBL genes (107,108). 
The MBL gene, the New Delhi metallo-beta-lactamase (NDM-1), was first described in 
December 2009 in a K. pneumoniae isolate from a Swedish patient who had been 
hospitalized in India (84). Subsequent reports have included patients who have travelled 
and undergone procedures (so called "medical tourism") in India and Pakistan (87), as 
well as cases reported in Asia, Europe, North America, the Caribbean, and Australia 
(85,87,109). 
In the United States, between January 2009 and February 2011, seven 
Enterobacteriaceae isolates with NDM-1 production were reported to the Centers for 
Disease Control and Prevention (CDC) (3). These were all identified in patients who 
had travelled to India or Pakistan, the majority of whom received medical care there. 
Isolates of P. aeruginosa which co-harbour genes for both KPC and NDM have also 
been described (110). 
 
A study done in Europe between 2008 and 2010, to assess the prevalence of NDM-1 
CRE, had 77 cases in 13 countries, with indications of an increase in the spread of such 
infections as the years progressed. Most cases gave history of recent travel to or 
hospitalisation in the Indian Subcontinent(111). 
Majority of the clinical isolates had blaNDM-1 determinant located on conjugative 
plasmids. Few isolates has the determinant on the bacterial chromosome, indicating 
intragenomic recombination. NDM-1 was produced by K. pneumoniae and E.coli 
isolates from the same patient which suggested in vivo transfer. 
These offer a characteristic potential for horizontal dissemination.  
Closer home a study done in Aga Khan University in Karachi, revealed that 94% of 
their isolates (n=104) were positive for blaNDM-1 gene. Klebsiella pneumoniae was most 
frequent isolate followed by E.coli. mortality among patients with bacteremic illness 
was approximately 57%.(112) 
It is these facts and figures that make the development of treatment guidelines 
imperative in CRE bacteremia. 
 
 
 
 
 
ANTIBIOTIC THERAPY(7) 
There is a lacuna in clinical data on the therapy of CRE BSI, hence treatment choice is 
often controversial. Results from RCTs, observational studies and case reports on KPC 
or VIM producing strains are inconsistent, due to differences in patient populations, 
causative bacteria and severity of illness. Combination of two or more drugs, to which 
the causative organism is susceptible or resistant have been used, with variations in 
doing regimens and treatment duration adds to the complexity of analysis. 
Treatment options include polymixins, some aminoglycosides and tigecycline which 
generally retain in vitro activity against CRE. 
Other options include high dose prolonged infusions of carbapenem therapy as a part of 
the combination regimen, when the carbapenem MIC <=4mg/L. 
Polymixin: 
Polymixins in use are of two types, Polymixin E (colistimethate) and Polymixin B. 
There are cyclic peptides that differ by 1 amino acid; they possess targeted Gram 
negative activity. Through an electrostatic interaction between the cationic polypeptide 
antimicrobial and the anionic lipopolysaccharide of the outer membrane of the bacteria, 
there is a resultant leakage of cellular contents and bacterial cell lysis. (113) 
Tigecycline:  
It is a glycycline which is bacteriostatic and binds to the 30S ribisomal subunit and 
therby inhibits protein synthesis.  The FDA has approved it for the treatment of skin 
infections and complicated abdominal infections and Community acquired pneumonia.  
Its  plasma concentrations however are relatively low and hence are often deemed to be  
to be inadequate to treat blood stream infections.(114) 
Fosfomycin: 
Is a phosphonic acid derivative, which is bactericidal against broad spectrum Gram 
positive and Gram negative organisms. 
Pyruvul transferase is a bacterial enzymes that is inactivated by fosfomycin, causing 
inhibition of bacterial cell wall synthesis. Fosfomycin has good dstribution into kidneys, 
bladder wall, prostate, lung, soft tissue, CSF and bone(115). 
Aminoglycosides: 
They inhibt protein synthesis by binding to the 30S subunit of the ribosome. They 
exhibit concentration dependant activity against gram negative bacteria and have a 
prolonged post antibiotic affect.(116)  
 
 
 
 
 
 
 
TREATMENT AND TREATMENT OUTCOMES 
Monotherapy: 
Colsitin has become the foundation against which treatment of CRE rests. Howver 
monotherpay With Colistin has been associated with exponentially high mortality rate 
exceeding 50%.(117) 
Monotherapy with Tigecycline has also come into question, due in part to the 
bacteristatic effect and the inadequate antibiotic concentrations in the serum. 
Fosfomycin, has been studied sparsely and possibly has a higher risk of emerging 
resistance during therapy(9). 
Combination therapy: 
Multiple in vitro studies have demonstrated that there is increased activity against CRE 
when antibiotics are given in cobination.  Synergistic effects have been observed for 
double and also triple combinations that could include  aminoglycosiders, aztreonam, 
carbapenem, colistin, rifampicin, tigecycline or fosfomycin. 
Colistin is often used as a part of the combination therapy as it acts as a detergent to 
increase the permeability of other antibiotics through the outer membrane of the 
bacteria(118). 
Clinical observational studies have demonstrated that combination therapy is superior 
to monotherapy when treating severe infectons due to CRE. 
Combinations that are frequently used include, colistin/tigecycline. 
Colistin/carbapenema, carbaenem/aminoglycoside and colistin/aminoglycoside.  
Fosfomycin can be used in strains that show resistance to colistin.(119) 
Patients with BSI with CRE are known to be associated  with high mortality, than 
patients with bacteremia due to susceptible organisms. BSI has also been known to have 
worse outcomes when compared to infections at other sites. 14 day  and  in-hospital, all 
cause mortality, of patients with CRKP BSI  was deemed to be 42% and 58% 
respectively in a case series of 60 patients. Risk factores for mortlaity included  
increased markers of chronic or acute morbidity , such as Pitts bacteremia score and 
APACHE II(121) . 
Optimal therapy still remains a poorly answered question as most treatment decisions 
are made on observational studies alone. 
A recent randomised control trial looked at treatment outcome after comapring colistin 
monotherapy to combiantion therapy of Colistin + Carbapenem. The primary outcome 
was all cause mortality at 14 days and secodnary outcome looked at mortality at 24 
days. There was no significant difference in outcomes, both at 14 and 24 days between 
the two groups (120). 
Other recent evidence suggets that among CRE BSI, a scoring system for low and high 
risk can predict mortality, INCREMENT CPE score. From Januray 2004 to December 
2013, 480 patients with CRE BSI were recruited for this study. Klebsiella pneumoniae  
was the most frequent organism. Appropriate therapy, which was defined as receipt of 
at least one antimicrobial with in vitro acivity agaisnt the isloate in queation was 
associated with lower mortality. Among paitents with a low mortality score (0-7) there 
was no significant difference in outcome between groups that received monotherpay 
and combination therapy. A significant reduction in mortality was ascertained in the 
high mortality score (8-15), in patients that received combination therapy.(12) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This thesis wishes  to address the following questions, and in the course of doing so, 
shed some light on appropriate antibiotic therapy for this threat to the healthcare system. 
1. Prevalence of CRE bacteremia in a tertiary hospital in South India 
2. Outcome (mortality) among patients with CRE BSI  
3. Factors associated with mortality among patients with CRE BSI (exposure 
variables: demographic variables, primary source of bacteremia, severity of 
illness, carbapenem MIC, types of carbapenemases, appropriateness of empiric 
antibiotic treatment). 
 
 
 
 
 
 
 
 
 
 
RESULTS 
This prospective cohort study was done from May 2017 to August 2018. 
 200 patients with blood stream infection with Carbapenem Resistant Enterobactericeae 
were initially sought for inclusion in this thesis. After application of the exclusion 
criteria 163 patients were recruited.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of patients with Carbapenem Resistant 
Enterobactericeae bloodstream infection from May 2017 to 
August 2018 
200 
 
Number recruited in 
this study 
163 
Did not consent: 9 
Polymicrobial 
infection: 5 
<18 years of age: 4 
Not an in-patient: 6 
Second isolate of 
CRE in same 
admission: 13 
 
Escherichia 
coli 
(n=77) 
Klebsiella 
pneumoniae 
(n=88) 
Survived 
40 
Adverse 
outcome 
37 
Survived 
31 
Adverse 
Outcome 
55 
Figure 1: Strobe Diagram 
PATIENT CHARACTERISTICS 
 
163 patients were included in this study after obtaining written informed consent. 
Of the 163 patients recruited in the study, 60% (n=98) were male and 40 %( n=65) were 
female. 
 
                             Chart 1: Gender distribution. N=163  
 
 
 
 
 
 
98, 60%
65, 40%
GENDER DISTRIBUTION
male female
The mean age of patients recruited in this study was 47.56 ± 17.48 years.  
 
             Chart 2: Age Distribution n=163 (x axis: age; y axis: frequency in numbers) 
A majority (64%) of the participants were categorised as unemployed, which included 
students, housewives and retired personnel. 
 
              Chart 3: Distribution of occupational status n=163 
64%5%
12%
6%
7%
2% 4%
Occupational Status
unemployed unskilled semi skilled skilled
clerical semi profession profession
29.4% (n=48) of the patients had systemic hypertension, and 30.7% (n=50) had diabetes 
mellitus.  6 patients tested positive for HIV, Hepatitis B and Hepatitis C cumulatively 
(n=1, n=3, n=6, respectively). 28.8% (n=47) patients had an underlying malignancy, of 
which 30 were haematological and 17 were non haematological. 
 
 
       Chart 4: Distribution of Systemic Hypertension, n=163 
 
 
          Chart 5: Distribution of Diabetes Mellitus, n=163 
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50, 31%
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Table 1: Demographic Characteristics, n=163 
 
 
 
 
 
Characteristic Number(%) n=163 
Gender                   Male 
                                Female 
98 (60.1) 
65 (39.9) 
Mean Age(years) 47.56 ± 17.58 
Systemic Hypertension 48 (29.4) 
Diabetes Mellitus 50 (30.7) 
Malignancy 
              Haematological 
              Non-Haematological 
47 (28.8) 
30 (18.8) 
17 (10.4) 
HIV Infection 1 (0.6) 
Hepatitis B Infection 3 (1.8) 
Hepatitis C Infection 2 (1.2) 
CLINICAL CHARACTERISTICS 
Of the patients who had Carbapenem-resistant isolates of Klebsiella spp. or Escherichia 
coli, 109 (66.9%) has history of previous hospitalisation.  162 of these were febrile on 
day 1 (day of blood culture being taken). 
On the day of taking the blood culture that grew the isolate of interest, 125 (76.7%) 
were hypotensive (systolic blood pressure <90 mm Hg) and 84 (51.5%) had an acute 
kidney injury. 
63 (38.7%) needed mechanical ventilation, and 54 (33.1%) suffered a cardiac arrest. 
In order to objectively evaluate the severity of their illness APACHE II score was 
calculated at the time of recruitment, and the mean APCHE II score was 24.90 ± 10.86. 
 
Chart 6: Distribution of APACHE II score in the cohort (x axis: APACHE II score, y 
axis: frequency in numbers) 
 Chart 7: Distribution of APACHE II score stratified based on organism grown (x axis: 
APACHE II scores, y axis: frequency in numbers) 
 
 
 
 
 
Pitt’s Bacteremia Score was also calculated with a mean value of 8 ± 4.6. 
 
Chart 8: Distribution of Pitt’s Bacteremia Score in the cohort, n=163 (x axis: Pitt’s 
Bacteremia score, y axis: frequency in numbers) 
Patients had a mean oral temperature of 102.1 ± 1.766 °F, with a mean MAP of 66 ± 
13.89 mm Hg.  
 
 
 
 
 
 
 
 Mean GCS (Glasgow Coma Scale) was 11.2± 3.60. 
 
   Chart 9: Distribution of GCS in the cohort, n=163 (x axis: GCS, y axis: frequency in 
numbers) 
 
 
 
 
 
 
Table 2: Clinical Characteristics (n=163) 
Characteristic Number (%) Median IQR 
(25th centile, 
75th centile) 
Previous 
Hospitalisation 
109 (66.9)   
Hypotension 
Systolic Blood 
Pressure <90mmHg 
125 (76.7)   
Mechanical 
Ventilation 
63 (38.7)   
Cardiac Arrest 54 (33.1)   
Mental Status 
       Alert 
       Disoriented 
        Stuporous 
      Comatose 
 
21 (12.9) 
37 (22.7) 
61 (31.4) 
44 (27) 
  
Acute Kidney Injury 84 (51.5)   
Temperature(°F) 102.12 ± 1.766 103 101,103 
Mean Arterial 
Pressure (mmHg) 
66 ± 13.89 65 60,73 
APACHE II 24.90 26 18,31 
Pitt’s Bacteremia 
Score 
8 ± 4.6 8.01 4,13 
 
 
 
 
 
 
 
 
 
 
 
LABORATORY CHARACTERISTICS 
The mean total counts for patients in this study were 11,694 ± 11008 cells/mm, which 
represents the wide range of leukopenia and leukocytosis that can be seen in sepsis. 
Mean values for creatinine were 2.09 ± 2.2 mg/dl, with haematocrit being 25.16 ± 5.56 
on an average. 
 
Chart 10: Distribution of total WBC count the cohort, n=163 (x axis: total WBC count 
in cells/ccmm; y axis: frequency in numbers) 
 
 
  
 
Of the 163 Carbapenem-resistant Enterobactericeae isolates, 77 (47.2%) were 
Escherichia coli and 86 (52.8%) were Klebsiella spp. 
 
 
Chart 11: Distribution of CRE organism in the cohort, n=163 
Primary source of infection: The source of bacteremia was determined to be primary 
BSI, which included 12 CLABSI, in 104 (63.8%), pneumonia (lung) in 16 (9.8%), 
urinary tract in 21 (12.9%), gastrointestinal tract in 10 (6.1%) and soft tissue infections 
in 22 (7.4%). 
77, 47%
86, 53%
ORGANISM
E.coli Klebsiella
  
Chart 12: Distribution of primary source of infection, n=163 
 
15 (9.2%) had features of other infections during the course of their hospital admission, 
this was predominantly seen in patients with haematological malignancies, with 
profound neutropenia, who had developed concomitant fungal infections. 
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SOURCE OF INFECTION
blood pneumonia urinary tract gastrointestinal NSTI
Of the empiric antibiotics used, Cefoperazone-Sulbactam was used in 31 (19.01%), 
Piperacillin-Tazobactam in 19 (11.7%) and Meropenem in 113 (69.3%). 
 
 
Chart 13: Empiric antibiotic use in the cohort, n=163 (x axis: empiric antibiotics used; 
y axis: frequency in numbers) 
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Table 3: Laboratory Parameters 
Laboratory Parameters Number (%) 
Mean Total WBC count 
(cells/ccmm) 
11694 ± 11008 
Mean Serum Creatinine (mg/dl) 2.6 ± 2.2 
Mean Haemoglobin (G/dl) 25.16 ± 5.56 
CRE Organism 
       E. coli 
       Klebsiella spp 
     
 
77 ( 47.2) 
86 (52.8) 
Source of Bacteremia 
   Primary Blood Stream 
   Pneumonia (lung) 
   Urinary Tract Infection 
    Gastrointestinal 
    SSTI 
 
104 (63.8) 
16 (9.8) 
21 (12.9) 
10 (6.1) 
12 (7.4) 
Other Infections 15 (9.2) 
Empiric Antibiotics 
   Cefoperazone-Sulbactam 
   Piperacillin-Tazobactam 
   Meropenem 
 
31 (19) 
19 (11.7) 
113 (69.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
OUTCOME 
Cumulative all-cause mortality at day 14 (from the date of positive blood culture was 
obtained) was the primary outcome of interest for the purpose of this study. Discharge 
against medical advice was also considered an adverse outcome. In this regard, of the 
163 patients, 73 (44.8%) died during the 14 day follow up period of this thesis, while 
19 (11.7%) were discharged against medical advice. Revised adverse outcome is 92 
(56.4%). 
 
 
Chart 14: Primary outcome, n=163 (x axis: outcome of interest, y axis frequency of 
outcome in numbers) 
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 Chart 15: Distribution of revised outcome (Death+DAMA), n=163 
 
Among the two isolates of interest, patients with Escherichia coli in the blood stream 
37 of 77 had an adverse outcome (48.1%) and 55 of 86 (64%) patients with Klebsiella 
spp had an adverse outcome, in univariate analysis, this was found to be statistically 
significant with an OR 0.52 (95% CI 0.27-0.9760) p =  0.042 . 
Overall survival probability in this cohort was 79% at 3 days, 69% at 7 days and 44% 
at 14 days. Mean estimate for survival is 10.15 days with standard error of 0.04 (95% 
CI 9.37-10.93).  This is represented in the following Kaplan Meier graph. 
71, 44%
92, 56%
REVISED OUTCOME- ADVERSE EVENTS
Improved Death/DAMA
 Chart 16: Survival Analysis, in percentage on the y axis and follow up time on the x 
axis. (Mean estimate for survival is 10.15 days with standard error of 0.04 (95% CI 
9.37-10.93) while median was 14). 
Mean survival time for E.coli was 10.78 with standard error of 0.55 (95% CI of 9.69-
11.86), while for Klebsiella spp it was 9.53 with standard error of 0.573 (95% CI 9.37-
10.93). Survival analysis revealed Hazard ratio of 1.48 (95%CI 0.97 -2.24) p=0.068 
with a greater risk of death in patients with Klebsiella spp than with Escherichia coli. 
 
 Chart 17: Survival analysis categorised by organism, y axis: survival probability in 
percentages, x axis: survival in days. (Estimates for survival in Mean: 10.779 for E.coli, 
9.593 for Klebsiella spp) 
Predictors for an adverse outcome considered were, comorbid illnesses like diabetes 
mellitus, systemic hypertension, presence of an underlying malignancy and Charlson 
Comorbidity Index, severity of illness as measured by validated scores like APACHE 
II, Pitts Bacteremia score and INCREMENT CPE score. 
 
 
 
 
Table 4: 14 day treatment outcomes 
Treatment Outcome Number (%) 
Death 73 (44.8) 
Discharged Against Medical Advice 
(DAMA) 
19 (11.7) 
Improved 71 (43.6) 
Adverse Outcome 
(Death  + DAMA) 
92 (56.4) 
 
Table 5: Treatment outcomes stratified according to organism 
Organism Outcome Number (%) 
Escherichia coli Survived 
Adverse Outcome 
40 (48.1) 
37 (51.9) 
Klebsiella spp Survived 
Adverse Outcome 
31 (36) 
55 (64) 
 
 
 Table 6: Univariate and multivariate Cox regression analysis for adverse outcomes of 
patients with Carbapenem-resistant Enterobactericeae bloodstream infection. (n=163)  
Characteristic Univariate Analysis 
OR   (95%CI)             p value 
Multivariate Analysis 
OR  (95%CI)             p value 
Age (years) 
       <45* 
       45-70 
       >70 
 
 
1.2 (0.63-2.35)                 0.556 
0.75 (0.23-2.23)               0.576 
 
Male gender 0.75 (0.416-1.45)             0.456  
Escherichia coli* 
Klebsiella spp. 
 
0.52 (0.27-0.9760)           0.042  
 
Source 
   Primary BSI 
 
2.20 (1.15-4.26)               0.017 
 
2.44 (1.05-5.921)             .049 
Charlson Comorbidity 
Index 
0.827 (.393-1.738)           0.616  
Mechanical Ventilation 12.4 (4.1-37.2)               <0.001  22.5 (8.26-61)                 <0.001 
Septic Shock 7.63 (3.23-18.24)           <0.001  
Mental Status: not 
alert 
2.92 (1.34-7.84)               0.027 2.4 (1.05-5.92)                  0.049 
Malignancy 0.831 (0.42-1.64)             0.594  
CPE increment Score 
(high mortality score 8-
15) 
10.23 (4.75-22)              <0.001 4.29 (1.13-14)                   0.017 
Pitt’s Bacteremia Score 
(>4) 
9.33 (3.59-24)                <0.001 4.42 (0.8-23)                 0.079 
* Reference index 
Age and gender were not found to be significant predictors of mortality.  Significant 
difference in mortality was seen among the isolates, with 55 of 86 (64%) patients with 
Klebsiella spp. in blood having an adverse outcome (OR 0.52, 95% CI 0.27-0.976, 
p=0.042) compared to E.coli bacteremia. 
In univariate analysis we found that, primary blood stream infections, which included 
catheter related blood stream infections were also associated with a significant increase 
in mortality when compared to other sources of bacteremia (OR 2.44, 95% CI 1.5-
5.921,p =0.049). Other variables that were significantly associated with mortality in 
multivariate analysis were, hypotension at presentation (OR 7.63, 95% CI 3.23-18.24, 
p=<.001), mechanical ventilation (OR 12.4, 95% CI 4.1-37.2,p =<0.01), altered mental 
status (OR 2.92, 95%CI 1.34-7.84, p=0.027), Pitt’s Bacteremia Score of >4 (OR 9.33, 
95% CI 3.59-24, p=<0.001) and INCREMENT CPE score between 8-15 (OR 10.23, 
95%CI 4.75-14, p=<0.001). There was no significance in mortality based on Charlson 
Comorbidity Index presence of underlying malignancy or the Urinary Tract as primary 
source on infection.  
 
During this study the antibiotics prescribed were left to the discretion of the treating 
physician.  
All patients received an appropriate targeted therapy, which by the definition used was 
at least 1 antimicrobial with in-vitro sensitivity to the isolate of interest. Monotherapy 
was used in only 7 out of 163 patients (4.29%). Combination therapy used comprised 
of Colistin, Tigecycline and Teicoplanin containing regimens. 
The combination of Meropenem with Colistin, 99 (60.7%) was used maximally in the 
Medicine Wards and Medical ICU in out institution , while a trend towards preferring 
Tigecycline with Colistin +/- Meropenem, 25(15.3%) was seen among the surgical 
wards and the Surgical ICU. 
There was no significant difference observed in mortality between combination therapy 
regimens, however combination therapy had better outcomes than monotherapy. 
Antibiotic sensitivity was not available for all isolates. Much of the unavailable data is 
from patients who succumbed to their illness prior to attainment of the sensitivity 
pattern. Data on amikacin, colistin, tigecycline, fosfomycin and minocycline have 
been analysed. These are the antimicrobials that are available to treat CRE infections. 
Data on susceptibility is available on, 130/163 for amikacin, 97/163 for colistin, 1/163 
minocycline, 18/163 for fosfomycin and 82/163 for tigecycline. 
 
Out of the data available, valid percentages of susceptibility extrapolated to 163 is as 
follows: 
 19% susceptible to amikacin, 
83% susceptible to colistin, 
67% susceptible to fosfomycin 
77% susceptible to tigecycline. 
 
 
 Chart 18: Distribution of antimicrobial susceptibility, x axis: antimicrobials, y axis: 
validated susceptibility in percentages (S: susceptible; R: resistant) 
Table 7: Mortality of patients receiving appropriate therapy according to 
antimicrobials administered and the INCREMENT CPE mortality score strata. 
Antimicrobial All Patients 
N=163 (%) 
Low 
Mortality 
Score(0-7) 
High 
Mortality 
Score     
(8-15) 
Adverse 
Outcome 
(%) 
Colistin 1 (0.6) 1(100) 0 1(100) 
Tigecycline 1 (0.6) 1 (100) 0 1 (100) 
Teicoplanin 5 (3) 1 (20) 4 (80) 5 (100) 
Colistin + 
Meropenem 
99 (60.7) 40 (40.4) 59 (59.6) 49 (49.5) 
Colistin + 
Rifampicin 
6 (3.7) 3 (50) 3 (50) 3 (50) 
Tigecycline + 
Meropenem 
4 (2.5) 0 4 (100) 2 (50) 
Tigecycline + 
Colistin 
7 (4.3) 2 (28.6) 5 (71.4) 3 (42.9) 
Colistin + 
Teicoplanin 
12 (17.2) 2 (16.7) 10 (83.3) 9(75) 
Tigecycline + 
Meropenem + 
Colistin 
28 (17.26) 5 (17.9) 23 (82.1) 20 (71.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
This study was designed as a prospective cohort, to assess treatment outcomes in 
patients with Carbapenem Resistant Enterobactericeae blood stream infections 
which is an ever increasing threat in medical practice today. 
Over the period of May 2017 to August 2018, 200 patients were documented to have 
CRE bacteremia, of which 163 were included in this study. These numbers 
corroborate the increasing prevalence of CRE bacteremia, a study done in the Aga 
Khan University had 104 isolates (112) while a large study done across 13 centres 
in Europe has 77 CRE isolates .  A large study done over 10 centres from January 
2004 to December 2013 had 480 isolates. 
Among the 163 isolates, 86 (52.7%) were Klebsiella spp and 77 were Escherichia 
coli.  Most other studies find a significantly larger percentage of Klebsiella spp when 
compared to Escherichia coli. This is included 86% preponderance in the 
INCREMENT trial(119) and 57% in the study from Aga Khan University(112).  
Our primary objective was to look at treatment outcomes, where a 14 day all-cause 
mortality was the primary end point. Death and discharges against medical advice were 
considered as a composite adverse outcome.  92 of 163 (56.4%) had an adverse outcome 
in our study, which is comparable to all other studies done on CRE bacteremia.   
Survival analysis revealed Hazard ratio of 1.48 (95%CI 0.97 -2.24) p=0.068 with a 
greater risk of death in patients with Klebsiella spp than with Escherichia coli. 
 
Predictors of mortality that were looked at included a range of features, from 
demographic profile, to comorbid illnesses, severity of illness , primary source of 
infection and the organism cultured. 
Demographic characteristics 
60% of the participants in this study were male with a majority of the participants 
being categorised as unemployed.  
Mean age was 47.56 with 85(51.5%) of the participants within the 45-70 age group. 
A similar population distribution has been seen in most other studies on CRE 
bacteremia.  
Both sex and age were not significant predictors of mortality, this was not in 
corroboration with other studies where an increasing age was found to be associated 
with higher risk of mortality. 
One reason for this difference could be the very small number of people above the 
age of 70 recruited in this study (15 out of 163).    
Most of the women were housewives and the majority of the men were unemployed 
or retired personnel. 
 
 
 
 
Clinical Characteristics 
162 of the patients were febrile on day 1, deemed as the day the blood culture was 
drawn. Mean temperature ascertained during the course of this study was 102.12 
degree Fahrenheit. 
Majority of the patients were tachycardic and tachypnoeic, with the mean pulse rate 
being 110/min and mean respiratory rate was 29/min. 
Hypotension was noted in 125 of 163 patients (76.6%), with a mean Mean Arterial 
Pressure being 66mmHg and was associated with a significant risk of adverse 
outcome (OR7.63, 95% CI 3.23-18, p=<0.001). 
Patients who needed mechanical ventilation, during the course of their admission, 
were also found to have significantly higher risk for adverse outcomes (OR12.4, 
95%CI 4.1-37.2, p=<0.001). Similar observations were made in INCREMENT trial 
and the study from the Aga Khan University. 
Other clinical feature that had significant correlation with an adverse outcome was 
an altered mental status (OR 2.92, 85% CI 1.34-7.84, p=0.027). 
Among the comorbidities studied, 30.7 % had diabetes mellitus and 29.4% has 
systemic hypertension. 28.8% had an associated malignancy.  
In order to subjectively evaluate the patient’s condition at presentation, various 
validated scores were used, such as the APACHE II score, mean value calculated 
during this study was 24.90 which has a mortality of 40% associated with it. 
 
Other index that was calculated was the Charlson Comorbidity Index, of which the 
mean value attained was 2.24 for Escherichia coli and 2.86 for Klebsiella spp which 
is comparable to other studies like the INCREMENT trial(119). 
In terms of assessing the severity of illness, the Pitt’s bacteremia score and Increment 
CPE score were calculated for all participants. 
A Pitt’s Bacteremia Score of more than 4 is suggestive of a severe infection, in our 
study the mean value was  8.01  which was much higher that the values that were 
attained in the INCREMENT trial. A Pitt’s bacteremia score of more than 4 was also a 
significant predictor of mortality in this study (OR 9.33, 95% CI 3.59-24, p=<0.001). 
The INCREMENT CPE score which was validated in the INCREMENT trial, has cut 
off values for low and high mortality scores. 0-7 is associated with low mortality and 
8-15 is associated with high mortality, in this study the mean CPE score was 7.88 for 
patients with Escherichia coli isolates and 8.88 for Klebsiella spp. The CPE score was 
also a significant predictor of mortality (OR 1.23, 95% CI 4.75-22, p=<0.001). 
Our study had a preponderance of primary blood stream infections, where another 
source could not be delineated, and 104 of 163 (63.8%). Other similar studies have 
shown a 47.1% (25 of 53) (115) and 35.7% (20 of 58) (120) primary bloodstream 
infections. 
 
Antibiotic Regimens 
During the course of this study, there was no input by the investigators on the choice of 
antibiotics. Treatment decisions were left to the discretion of the treating physicians. 
Empiric Antibiotics that were used were Cefaperazone-Sulbactam, Piperacillin-
Tazobactam and Carbapenem (Meropenem). 113 of 163 (69.3%) used Meropenem as 
the empiric antibiotic of choice.  
Antibiotic sensitivity tests were reported within 48 hours and definitive therapy was 
initiated based on its report. 
Susceptibility pattern that has been ascertained through this study suggests that up to 
81% of our isolates are resistant to amikacin. Colistin has a susceptibility rate of 83% 
when extrapolated for the number of isolates we have information for, and tigecycline 
has a susceptibility rate of 77%.  
Among the definitive antimicrobials used, monotherapy was used in a very small 
proportion of patients, 7 of 163 (4.2%) all of whom has an adverse outcome. 
Among the combination therapies used, Colistin with Carbapenem, was used most 
frequently 99 of 163 (60.7%), with a mortality rate of 49.5%. 
28 of 163 had triple antibiotic with Tigecycline + Meropenem + Colistin, with 71.4% 
mortality, reflecting that patients who were sicker from the onset required a much more 
aggressive antibiotic regimen. 
 
 
CONCLUSIONS 
This prospective cohort study, aimed to look at treatment outcomes of patient’s with 
Carbapenem Resistant Enterobactericeae bloodstream infections. The overall 14 day 
all-cause mortality in patients with CRE BSI was 56.4%, being higher in with Klebsiella 
spp than with Escherichia coli infections. Primary blood stream infections place the 
patients at higher risk for an adverse outcome. 
Other significant predictors of mortality included both clinical and indicial parameters. 
Hypotension at presentation, requirement of mechanical ventilation and altered mental 
status were predictors of adverse outcomes. As were elevated INCREMENT CPE score 
(8-15, indicating high mortality score) and Pitts’ Bacteremia score of more than 4. 
Therapeutic options are limited, and among the available options combination therapy 
appears to be associated with better outcomes. Meropenem with Colistin is the most 
widely used combination of choice, especially in the Medical wars, while Tigecycline 
containing regimens are preferred in the surgical setting. 
 
 
 
 
 
 
 
 LIMITATIONS 
1. Short term follow up of 14 days does not give information on long term 
outcomes 
2. Carbapenem MIC were not available for most patients and hence correlation 
of low or high MIC with adverse outcomes could not be studied. 
3. Type of Carbapenemases was not evaluated in this study, hence its effect on 
the outcome could not be ascertained. 
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ANNEXURE 
ANNEXURE 1: IRB APPROVAL 
 
 
 
 
 
ANNEXURE 2: CONSENT FORM 
 
 
Treatment outcomes in patients with Carbapenem Resistant Enterobactericeae 
bacteremia and factors affecting mortality, a study done in a tertiary care hospital in South 
India. 
 
 
Subject ID:  ____________ 
 
Subject’s Name: _________________________________________ 
 
Date of Birth (if available): 
 
Age (in completed years): ___________________________ 
 
 
(i)  I confirm that I have read and understood the information sheet dated February 
1st 2017 for the above study and have had the opportunity to ask questions. [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [  ] 
 
(iii)  I understand that the study, the Ethics Committee and the regulatory authorities 
will not need my permission to look at my health records both in respect of the 
current study and any further research that may be conducted in relation to it, 
even if I withdraw from the study. I agree to this access. However, I understand 
that my identity will not be revealed in any information released to third parties 
or published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
 (v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative 
 
Date: _____/_____/______ 
 
Witness: ________________________ 
 
Signatory’s Name: _________________________________         Signature:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE 3: PATIENT INFORMATION FORM 
 
Treatment outcomes in patients with Carbapenem Resistant Enterobactericeae bacteremia 
and factors affecting mortality, a study done in a tertiary care hospital in South India. 
Date: February 1st 2017 
 
Gram negative bacilli like E.coli and Klebsiella are common pathogens that are encountered in 
hospital setting. However the over the past few decades there has been an increasing emergence 
of resistance to common antibiotics being used to treat these infections. After the emergence of 
ESBL and their subsequent treatment with carbapenems, there has now emerged resistance to 
carbapenems. This poses a novel threat to the treatment of these serious often life threatening 
infections. There it is imperative to study both treatment outcomes to be able to analyse 
appropriate antibiotic therapy for these infections. Any publications arising from the study will 
not have any patient identifiable data. You can opt out of the study if you wish to do so at any time. 
 
By enrolling yourself into this study you subject yourself to no added tests or investigations. This 
study will not influence the treatment that you are currently receiving.  Your treatment will not 
be altered in any form as a consequence of your participation in this study.  You will also be 
required to answer some questions regarding your health status at the beginning of this study.  
All information provided by you will be kept confidential and your identity will not be revealed 
to a third party under any circumstances.  
By participating in this study, you will go a long way in helping the health care community better 
understand the mechanisms of the illness so that diagnosis can be made early and correct 
treatment be instituted in time to prevent the many complications of the disease.  
Thank you 
 
Nalini Sarah Newbigging 
 
 
 
 
ANNEXURE 4: CASE REPORT FORM 
 
Treatment outcomes in patients with Carbapenem Resistant Enterobactericeae 
bacteremia and factors affecting mortality, a study done in a tertiary care hospital in South 
India. 
 
 
1. Serial no: □□□ 
2. Name: _________________________________________ 
3. Hospital number: □□□□□□□ 
4. Address: ______________________________________ 
________________________________________________ 
 
___________________________________________________ 
 
5. Phone no: 
6. Occupation: 
 
7. Age: in years: □□ 
8. Gender:   □ male (1) female (2)  
9. Height: in cms □□□ 
10. Weight: in kgs □□ 
11. BMI: □□.□□ 
 Comorbidities and baseline evaluation 
12. HTN:  □ Yes (1) no (2) 
13. DM: □ yes (1) no (2) 
14. Malignancy: □ (1) yes (2) no  
15. BBVS:  
 a.Hiv:  □ (1) yes (2) no 
 b. HepB: □ (1) yes (2) no 
 c.HebC: □ (1) yes (2) no 
16. Smoking: □ yes (1) no (2) 
17. Alcohol: □ yes (1) no (2) 
18. Previous hospitalization: □ yes (1) no (2) 
19. APACHE II SCORE: □□ 
A.Chronic organ insufficiency: □ yes (1) no (2)  if yes, then 
 □ (5 emergency surgery, 2 elective surgery, 5 not post op) 
B. temperature: ________  
C.Acute renal failure: □ (1) yes (2) no 
D.Mean Arterial pressure: _____ 
E.Pulse rate: 
F.Respiratory rate: 
g.Sodium: 
h.Potassium: 
i. Creat: □ <1.4(1) 1.4-2 (2) >2(3) 
j.Hematocrit: 
K.Total WBC: 
l.GCS: 
m.PaO2:  
20. Pitts bacteremia index: □ 
a.Temperature:_____ 
b.Hypotension: □ yes (1) no (2) 
C.Mechanical ventilation: □ yes (1) no (2) 
D.Cardiac arrest: □ yes (1) no (2) 
E.Mental status: □ (1) alert (2) disoriented (3) Stuporous (4) comatose 
 
TREATMENT 
21. CRE in blood: □ yes (1) no (2) 
22. Organism: □ (1) E.coli (2) Klebsiella 
23. Primary source: □ blood (1), lung (2), urine (3), other (9) 
24. Choice of antibiotic: □ meropenem (1) colistin (2) colistin+mero (3) 
tigecycline (4) 
 
 
OUTCOMES 
 
25. Febrile on day 1: □ yes (1) no (2) TEMP: ______________ 
26. Febrile on day 7: □ yes (1) no (2) TEMP: _________________ 
27. Febrile on day 14: □ yes (1) no (2) TEMP: _________________ 
28. Other infections: □ yes (1) no (2) 
29. Outcome: □ death (1) 
                          Improved (2) 
                         Discharged (3)  
30. Direct cost of treatment:  
31. 1 month survival: yes (1) no (2) 
32.3 month survival: yes (1) no (2) 
     
 
 
 
 
ANNEXURE 5: DATA SHEET 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
